U.S. Markets close in 5 hrs 33 mins

Top 3 Trends Impacting the Global Antiviral Drugs Market Through 2021: Technavio

Technavio announces the release of their Antiviral Drugs Market 2017-2021 report (Graphic: Business Wire) Multimedia Gallery URL


Technavio’s latest market research report on the global antiviral drugs market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170411006033/en/

Sapna Jha, a lead analyst from Technavio, specializing in research on infectious and rare diseases sector says, “The global antiviral drugs market is expected to grow at a CAGR of more than 9% during the forecast period, owing primarily to the increase in diseased population and technological advancements in the antiviral sector. The advancements in technology have resulted in the discovery of newer drugs offering greater efficiency with fewer side effects.”

Request a sample report: https://www.technavio.com/request-a-sample?report=55728

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

The top three emerging market trends driving the global antiviral drugs market according to Technavio healthcare and life sciences research analysts are:

  • Technological advancements
  • Combination therapy
  • Growing partnerships

Technological advancements

The new hybridoma technique is a novel approach toward the development of monoclonal antibodies, which are selective in nature. This technique will not only have a positive impact against viral diseases but also decrease the cost of the overall treatment. It can be expected that antiviral agents, which were above USD 100 and could be used to control an epidemic effectively, can now be produced at 1% of its original cost.

“Unlike vaccines, which take time to generate passive immunity in any individual and depend upon an individual’s own capability of developing immunity, monoclonal antibodies immediately develop immunity, and are independent of the individual's capability of developing immunity,” says Sapna.

Combination therapy

The use of combination therapy has proven to be beneficial to treat certain viral infections due to their synergistic effect. For example, the availability of more than 20 antiretroviral drugs has paved the way for exploring their efficacy when given in combination to treat hepatitis B infection.

This therapy helps to prevent drug resistance acquired by the viral organism as the treatment contains more than one drug. Most of the drugs employed in the treatment of HIV are given in combination with other drugs to combat the opportunistic infections in HIV patients. For example, the development of HIV-TB interventions to treat HIV-induced TB helped in decreasing the HIV-related mortality rate from 2014 to 2015 significantly.

Growing partnerships

The antiviral drugs market will witness partnerships between private manufacturers and public health agencies to promote cost-effective research. These research efforts are further used for preparing vaccines and antiviral drugs for future pandemics and to secure public health by increasing access to antiviral drugs. Also, such alliances are actively involved in raising public awareness through various campaigns. For instance, GlaxoSmithKline's public policy states its willingness to support and participate in research and funding of clinical trials for vaccines and antiviral drugs in pandemic situations.

Public health agencies such as WHO, National Institute of Health (NIH), and the CDC are actively involved in the reporting and sharing of information related to new viruses and related pandemic potential to support these manufacturers to enhance the development and bulk production of vaccines to immunize the public, thereby improving health standards globally.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like patient monitoring devices, urology devices, and vaccines. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170411006033/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/news/home/20170411006033/en/